Heterocyclic Tricyclic Sulfonamides Modulate PP2A for Drug-Resistant Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate and breast cancers, particularly castration-resistant prostate cancer and triple-negative breast cancer, lack curative options and are hindered by drug resistance, necessitating new therapeutic approaches that target specific signaling pathways and cellular mechanisms.
Innovation Solution
Development of heterocyclic constrained tricyclic arylsulfonamide derivatives that modulate Protein Phosphatase 2A (PP2A) activity, promoting FOXO1 transcription factor translocation to the nucleus and inducing anti-proliferative effects, which can be used as monotherapy or in combination with other drugs to restore chemotherapy sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for prostate and breast cancers are used, then existing therapy options are maintained, but drug resistance develops and curative options are lacking
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of sulfonamide compounds to create novel heterocyclic constrained tricyclic derivatives. These structural parameter changes result in compounds with enhanced ability to modulate PP2A activity and induce FOXO1 translocation, thereby overcoming drug resistance while maintaining therapeutic efficacy in castration-resistant prostate cancer and triple-negative breast cancer
Solution Approach 2:
The invention employs composite materials by combining multiple heterocyclic rings with constrained tricyclic structures and sulfonamide groups to create complex molecular architectures. This composite molecular design enables the compounds to simultaneously interact with multiple targets in the PP2A/FOXO1 signaling pathway, enhancing therapeutic reliability while preventing adaptive resistance mechanisms
2Reliability
If new therapeutic approaches targeting specific signaling pathways are developed, then therapeutic efficacy is improved, but treatment complexity increases
Solution Approach 1:
The patent uses an intermediary mechanism by designing compounds that target PP2A phosphatase, which serves as a key regulatory node in multiple signaling pathways. By modulating PP2A activity, these compounds indirectly regulate FOXO1 translocation and downstream apoptotic pathways, achieving enhanced therapeutic efficacy through a focused molecular target rather than complex multi-target interventions
Solution Approach 2:
The invention applies universality by creating compounds with broad applicability across different cancer types (prostate and breast cancer) through a single mechanism of action. The heterocyclic constrained tricyclic sulfonamides universally modulate PP2A/FOXO1 signaling regardless of cancer origin, simplifying treatment approaches while maintaining high therapeutic efficacy across diverse malignancies
Data Source
AI summary
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus:The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a therapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.